Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23060576)

1.

Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.

Yamauchi T, Matsuda Y, Takai M, Tasaki T, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Ueda T.

Anticancer Res. 2012 Oct;32(10):4479-83.

PMID:
23060576
2.

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H.

Leukemia. 1999 Mar;13(3):393-9.

PMID:
10086730
3.

WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.

Sakamoto Y, Mariya Y, Sasaki S, Teshiromori R, Oshikiri T, Segawa M, Ogura K, Akagi T, Kubo K, Kaimori M, Funato T.

Tohoku J Exp Med. 2009 Oct;219(2):169-76.

4.

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G; Piedmont Study Group on Myleodysplastic Syndromes.

J Clin Oncol. 2003 May 15;21(10):1988-95.

PMID:
12743153
5.

Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.

Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K.

Leuk Res. 2010 Aug;34(8):986-90. doi: 10.1016/j.leukres.2009.11.029. Epub 2010 Jan 19.

PMID:
20031209
6.

WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.

Pan L, Zhang XJ, Niu ZY, Suo XH, Zhang JY, Yang L, Liu XJ, Qiao SK, Dong ZR, Ohno R.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):501-7.

PMID:
16800930
7.

Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.

Iwasaki T, Sugisaki C, Nagata K, Takagi K, Takagi A, Kojima T, Ito M, Nakamura S, Naoe T, Murate T.

Pathol Int. 2007 Oct;57(10):645-51.

PMID:
17803653
8.

[Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome].

Cheng YF, Zhang LP, Liu YR, Qin YZ, Wu J, Liu GL.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):536-40. Chinese.

9.

[Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].

Lu D, Qin YZ, Li LD, Shi HX, Lai YY, Liu YR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):370-6. doi: 10.7534/j.issn.1009-2137.2014.02.019. Chinese.

PMID:
24763007
10.

WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?

Bader P, Niemeyer C, Weber G, Coliva T, Rossi V, Kreyenberg H, Gerecke A, Biondi A.

Eur J Haematol. 2004 Jul;73(1):25-8.

PMID:
15182334
11.

Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.

Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H.

Cancer Sci. 2010 Mar;101(3):594-600. doi: 10.1111/j.1349-7006.2009.01453.x. Epub 2009 Dec 4.

PMID:
20132220
12.

[Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].

Kitamura K, Nakano Y, Watamoto K, Koga D, Naoe T.

Rinsho Ketsueki. 2010 Dec;51(12):1748-55. Japanese.

PMID:
21258184
13.

The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.

Baba M, Hata T, Tsushima H, Mori S, Sasaki D, Turuta K, Hasegawa H, Ando K, Sawayama Y, Imanishi D, Taguchi J, Yanagihara K, Tomonaga M, Kamihira S, Miyazaki Y.

Intern Med. 2015;54(5):445-51. doi: 10.2169/internalmedicine.54.3123. Epub 2015 Jan 15.

14.

In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.

Pan L, Ohnishi K, Zhang WJ, Yoshida H, Maksumova L, Muratkhodjaev F, Shigeno K, Nakamura S, Luo JM, Hao HL, Fujisawa S, Naito K, Shinjo K, Takeshita A, Ohno R.

Leukemia. 2000 Sep;14(9):1634-41.

PMID:
10995011
15.

[Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].

Yang JK, Li JL, Li ZG, Li ZG, Liu PJ, Li JY, Lü HR, Deng Q, Lin XM, Cao JN.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003 Sep;15(9):557-9. Chinese.

PMID:
12971856
16.

High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.

Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D.

Blood. 1997 Aug 1;90(3):1217-25.

17.

[Expression of WT1 gene in patients with myelodysplastic syndrome and acute leukemia].

Lu Y, Jin J, Xu WL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Aug;12(4):464-6. Chinese.

PMID:
15363132
18.

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.

Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M.

Cancer. 2004 May 1;100(9):1884-91.

19.

Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.

Rauw J, Wells RA, Chesney A, Reis M, Zhang L, Buckstein R.

Leuk Res. 2011 Oct;35(10):1335-8. doi: 10.1016/j.leukres.2011.05.001. Epub 2011 Jun 24.

PMID:
21704372
20.

Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.

Nagai K, Kohno T, Chen YX, Tsushima H, Mori H, Nakamura H, Jinnai I, Matsuo T, Kuriyama K, Tomonaga M, Bennett JM.

Leuk Res. 1996 Jul;20(7):563-74.

PMID:
8795690
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk